The trajectory of companies tied to the drug's legacy presents a intricate investment picture . While the initial success generated substantial gains, generic alternatives have significantly impacted revenue. Investing in associated pharmaceutical firms now requires a thorough assessment of intellectual property safeguards, evolving healthcare chan